QR code

Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case series is unique in its focus on the intracran...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Illaa Smesseim, MD, Tijmen van der Wel, MD, Sushil K. Badrising, MD, PhD
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2024-12-01
Reeks:JTO Clinical and Research Reports
Onderwerpen:
RET
Selpercatinib
Non–small-cell lung carcinoma
RET fusion
NSCLC
Case Report
Online toegang:http://www.sciencedirect.com/science/article/pii/S2666364324001000
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items